SEC Filing | Kymera Therapeutics, Inc.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

View:

Download DOC

Download PDF

Download XLS

Download XBRL

kymr-10q_20210630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number: 001-39460

KYMERA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	81-2992166
(State or other jurisdiction of incorporation or organization	(I.R.S. Employer Identification No.)

200 Arsenal Yards Blvd., Suite 230 Watertown, Massachusetts	02472
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (857) 285-5300

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

KYMR

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 30, 2021, the registrant had 51,039,817 shares of common stock, $0.0001 par value per share, outstanding.

Summary of the Material and Other Risks Associated with Our Business

•

We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.

•

We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.

•

We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.

•

We are very early in our development efforts and our IRAK4, IRAKIMiD, and STAT3 programs are still in preclinical or early clinical development. If we are unable to advance them into and through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

•

Our approach to the discovery and development of product candidates based on our Pegasus platform is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.

•

Business interruptions resulting from the coronavirus disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business.

•

We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

•

If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

•

Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

•

Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

•

We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.

•

If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, express or implied statements about:

•

the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and future clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

•

our ability to continue to construct Pegasus, our drug discovery platform, and to enable a rational and effective drug discovery and development engine;

•

the timing and the success of preclinical and clinical studies under our IRAK4, IRAKIMiD, and STAT3 programs;

•

our plans to submit investigational new drug applications to the FDA for current and future product candidates;

•

the subsequent initiation of planned clinical trials;

•

our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;

•

our potential ability to manufacture our drug products, drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;

•

the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;

•

our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;

•

our ability to obtain and maintain regulatory approval of our product candidates;

•

our ability to commercialize our products, if approved;

•

the pricing and reimbursement of our product candidates, if approved;

•

the implementation of our business model, and strategic plans for our business, product candidates, and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•

estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;

•

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

•

future agreements with third parties in connection with the commercialization of product candidates and any other approved product;

•

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

•

our financial performance;

•

the rate and degree of market acceptance of our product candidates;

•

regulatory developments in the United States and foreign countries;

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

•

the success of competing therapies that are or may become available;

•

our ability to attract and retain key scientific or management personnel;

•

the impact of laws and regulations;

•

developments relating to our competitors and our industry;

•

the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials;

•

our expectations regarding the time during which we will continue to be an emerging growth company or smaller reporting company as defined in federal securities regulations; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

iii

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss	2
	Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31
PART II.	OTHER INFORMATION	32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	75
Item 3.	Defaults Upon Senior Securities	75
Item 4.	Mine Safety Disclosures	75
Item 5.	Other Information	75
Item 6.	Exhibits	76
Signatures		77

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share amounts)

(Unaudited)

	June 30, 2021			December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	84,903		$	31,004
Marketable securities (Note 4)		274,204			265,198
Accounts receivable—due from related parties		—			577
Contract assets—due from related parties		904			856
Prepaid expenses and other current assets		4,795			4,704
Total current assets	$	364,806		$	302,339
Marketable securities, non-current (Note 4)		45,305			162,531
Property and equipment, net (Note 6)		12,118			10,841
Right-of-use assets, operating leases		9,648			9,845
Other non-current assets		920			30
Restricted cash		1,589			1,589
Total assets	$	434,386		$	487,175
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	8,177		$	4,368
Accrued expenses (Note 8)		14,668			10,330
Deferred revenue		82,263			92,552
Operating lease liabilities		2,425			2,572
Finance lease liabilities		1,038			689
Other current liabilities		114			106
Total current liabilities	$	108,685		$	110,617
Non-current liabilities
Deferred revenue, net of current portion		52,672			77,838
Operating lease liabilities, net of current portion		13,696			14,128
Finance lease liabilities, net of current portion		1,145			604
Other non-current liabilities		84			100
Total liabilities	$	176,282		$	203,287
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 0 shares issued or outstanding as of June 30, 2021 and December 31, 2020		—			—
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020, 45,401,203 and 44,592,288 shares issued at June 30, 2021 and December 31, 2020, respectively; 45,327,681 and 44,482,186 shares outstanding at June 30, 2021 and December 31, 2020, respectively		5			4
Additional paid-in capital		424,599			412,777
Accumulated deficit		(166,500	)		(128,765	)
Accumulated other comprehensive loss		—			(128	)
Total stockholders’ equity		258,104			283,888
Total liabilities and stockholders’ equity	$	434,386		$	487,175

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three and Six Months Ended June 30, 2021 and 2020

(In thousands, except for share and per share amounts)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Collaboration Revenue—from related parties	$	18,519		$	3,288		$	37,221		$	6,716
Operating expenses:
Research and development	$	35,220		$	13,819		$	61,181		$	25,935
General and administrative		8,029			3,661			13,939			6,220
Total operating expenses		43,249			17,480			75,120			32,155
Loss from operations		(24,730	)		(14,192	)		(37,899	)		(25,439	)
Other income (expense):
Interest Income		98			228			217			577
Interest Expense		(28	)		(25	)		(53	)		(59	)
Total other income:		70			203			164			518
Net loss	$	(24,660	)	$	(13,989	)	$	(37,735	)	$	(24,921	)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities		14			(189	)		128			25
Total comprehensive loss	$	(24,646	)	$	(14,178	)	$	(37,607	)	$	(24,896	)
Reconciliation of net loss to net loss attributable to common stockholders:
Net Loss	$	(24,660	)	$	(13,989	)	$	(37,735	)	$	(24,921	)
Deemed dividend from exchange of convertible preferred stock		—			—			—			(9,050	)
Net loss attributable to common stockholders	$	(24,660	)	$	(13,989	)	$	(37,735	)	$	(33,971	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.55	)	$	(6.98	)	$	(0.84	)	$	(17.18	)
Weighted average common stock outstanding, basic and diluted		45,094,238			2,002,825			44,873,083			1,977,720

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

For the three months ended June 30, 2020 and 2021

(In thousands, except for share amounts)

(Unaudited)

	Series Seed Convertible Preferred Stock				Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Series B-1 Convertible Preferred Stock				Series C Convertible Preferred Stock				Common Stock				Additional Paid in		Accumulated			Accumulated Other Comprehensive			'Total Stockholders’
	Shares		Value		Shares		Value		Shares		Value		Shares		Value		Shares		Value		Shares		Value		Capital		Deficit			Loss			Equity
Balance at March 31, 2020		3,000,000	$	5,900		12,786,718	$	25,398		16,009,845	$	64,718		3,059,695	$	14,025		15,527,943	$	101,180		1,975,813	$	—	$	82	$	(94,105	)	$	220		$	(93,803	)
Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5)		—		—		55,394	111			—		—		—		—		—		—		—		—		—		—			—			—
Issuance of Series B Preferred Stock, net of issuance costs of $0		—		—		—		—		—		—		—		—		—		—		—		—		—		—			—			—
Issuance of Series C Preferred Stock, net of issuance costs of $320		—		—		—		—		—		—		—		—		—		—		—		—		—		—			—			—
Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock		—		—		—		—		—		—		—		—		—		—		—		—		—		—			—			—
Exercise of stock options		—		—		—		—		—		—		—		—		—		—		16,106		—		28		—			—			28
Vesting restricted stock		—		—		—		—		—		—		—		—		—		—		44,037		—		—		—			—			—
Stock-based compensation expense		—		—		—		—		—		—		—		—		—		—		—		—		664		—			—			664
Unrealized gain on marketable securities		—		—		—		—		—		—		—		—		—		—		—		—		—		—			(189	)		(189	)
Net Loss		—		—		—		—		—		—		—		—		—		—		—		—		—		(13,989	)		—			(13,989	)
Balance as of June 30, 2020		3,000,000	$	5,900		12,842,112	$	25,509		16,009,845	$	64,718		3,059,695	$	14,025		15,527,943	$	101,180		2,035,956	$	—	$	774	$	(108,094	)	$	31		$	(107,289	)

Balance at March 31, 2021		—	$	—		—	$	—		—	$	—		—	$	—		—	$	—		44,879,376	$	4		417,096	$	(141,840	)	$	(13	)	$	275,247
Exercise of stock options		—		—		—		—		—		—		—		—		—		—		422,471		1		1,470		—			—			1,471
Vesting restricted stock		—		—		—		—		—		—		—		—		—		—		18,154		—		—		—			—			—
Issuance of shares under employee stock purchase plan		—		—		—		—		—		—		—		—		—		—		7,680		—		307		—			—			307
Stock-based compensation expense		—		—		—		—		—		—		—		—		—		—		—		—		5,726		—			—			5,726
Unrealized gain on marketable securities		—		—		—		—		—		—		—